CAN
AZN icon

Cetera Advisor Networks’s AstraZeneca AZN Stock Holding History

Cetera Advisor Networks’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$4.28M Buy
31,592
+287
+0.9% +$38K 0.02% 689
2023
Q4 		$4.22M Sell
31,305
-686
-2% -$89.2K 0.02% 648
2023
Q3 		$4.33M Buy
31,991
+5,160
+19% +$705K 0.03% 571
2023
Q2 		$3.84M Buy
26,831
+1,966
+8% +$289K 0.03% 602
2023
Q1 		$3.45M Buy
24,865
+595
+2% +$80.1K 0.03% 631
2022
Q4 		$3.29M Buy
24,270
+14,267
+143% +$1.79M 0.03% 604
2022
Q3 		$1.1M Buy
10,003
+417
+4% +$52.9K 0.01% 841
2022
Q2 		$1.27M Sell
9,586
-1,918
-17% -$252K 0.02% 780
2022
Q1 		$1.53M Buy
11,504
+1,002
+10% +$120K 0.02% 729
2021
Q4 		$1.22M Sell
10,502
-2,482
-19% -$292K 0.02% 810
2021
Q3 		$1.56M Buy
12,984
+7,183
+124% +$836K 0.02% 649
2021
Q2 		$695K Buy
5,801
+1,764
+44% +$194K 0.01% 997
2021
Q1 		$401K Sell
4,037
-4,028
-50% -$405K 0.01% 980
2020
Q4 		$806K Sell
8,065
-587
-7% -$62.2K 0.02% 607
2020
Q3 		$948K Buy
8,652
+5,938
+219% +$660K 0.02% 497
2020
Q2 		$287K Buy
2,714
+167
+7% +$17.2K 0.01% 929
2020
Q1 		$228K Sell
2,547
-100
-4% -$9.41K 0.01% 931
2019
Q4 		$259K Buy
2,647
+149
+6% +$14K 0.01% 1025
2019
Q3 		$223K Sell
2,498
-293
-10% -$25.4K 0.01% 1051
2019
Q2 		$231K Buy
+2,791
New +$219K 0.01% 1024
2018
Q2 		– Sell
-2,926
Closed -$200K – 842
2018
Q1 		$200K Sell
2,926
-250
-8% -$17.3K 0.01% 811
2017
Q4 		$217K Sell
3,176
-163
-5% -$11K 0.01% 883
2017
Q3 		$224K Sell
3,339
-317
-9% -$20K 0.01% 794
2017
Q2 		$247K Sell
3,656
-533
-13% -$34.8K 0.01% 756
2017
Q1 		$258K Sell
4,189
-500
-11% -$29.1K 0.01% 747
2016
Q4 		$253K Sell
4,689
-1,439
-23% -$81.7K 0.01% 708
2016
Q3 		$403K Buy
6,128
+2,769
+82% +$181K 0.02% 650
2016
Q2 		$203K Buy
+3,359
New +$195K 0.01% 758
2014
Q3 		– Sell
-2,910
Closed -$215K – 823
2014
Q2 		$215K Sell
2,910
-220
-7% -$15.9K 0.01% 719
2014
Q1 		$201K Buy
+3,130
New +$202K 0.01% 712

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cetera Advisor Networks's AZN Position: Q1 2024 in Review

Cetera Advisor Networks increased its AstraZeneca (AZN) stake by 0.92% in Q1 2024, buying an estimated $38K and bringing the position to 31,592 shares worth $4.28M. The position accounts for 0.02% of the portfolio, ranked #689.

Cetera Advisor Networks first reported a position in AZN in Q1 2014 and has held it in 30 quarters since. The position peaked at $4.33M in Q3 2023. 1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

  • Cetera Advisor Networks held 31,592 shares of AstraZeneca worth $4.28M as of Q1 2024.
  • Cetera Advisor Networks bought 287 AstraZeneca shares in Q1 2024, an estimated $38K.
  • AstraZeneca made up 0.02% of Cetera Advisor Networks's portfolio in Q1 2024, its #689 holding.
  • Cetera Advisor Networks first reported a position in AstraZeneca in Q1 2014 and has held it in 30 quarters since.
  • Cetera Advisor Networks's AstraZeneca position peaked at $4.33M in Q3 2023.
  • 1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Cetera Advisor Networks's 13F filing for Q1 2024, filed 15 May 2024.